Standard BioTools Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 67.00K shares.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 458.00K shares, a 35.89% decline year-over-year.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 458.00K shares, a 35.94% decline from fiscal 2024.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 715.00K shares, a 1525.00% increase from fiscal 2023.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 44.00K shares, a 41.94% increase from fiscal 2022.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 31.00K shares, a 16.22% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 525.00K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 67.00K shares 10-Q · filed 2026-05-06 | 525.00K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 458.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 458.00K shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 714.43K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | 714.47K shares derived: sum of 4 quarters · filed 2025-08-15 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-06 | 714.95K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 714.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 715.00K shares 10-K · filed 2025-03-11 |
| 2024-09-30 | 42.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 573.00 shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 478.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | |
| 2024-03-31 | 53.00 shares 10-Q · filed 2024-05-09 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | 44.00K shares 10-K · filed 2024-03-01 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 31.00K shares 10-K · filed 2023-03-14 |
| 2022-09-30 | 2.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 31.00K shares derived: sum of 4 quarters · filed 2023-03-14 |
| 2022-06-30 | 21.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 30.00K shares derived: sum of 4 quarters · filed 2023-03-14 |
| 2022-03-31 | 8.00K shares 10-Q · filed 2022-05-09 | 45.00K shares derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 37.00K shares 10-K · filed 2023-03-14 |
| 2021-09-30 | 1.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 39.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2021-06-30 | 36.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | 136.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2021-03-31 | 0.00 shares 10-Q · filed 2021-05-07 | 100.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-12-31 | 2.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | 100.00K shares 10-K · filed 2022-03-08 |
| 2020-09-30 | 98.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 110.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | 13.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-05-11 | 144.00K shares derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | 12.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | 197.00K shares 10-K · filed 2022-03-08 |
| 2019-09-30 | 1.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | |
| 2019-06-30 | 131.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | |
| 2019-03-31 | 53.00K shares 10-Q · filed 2019-05-07 | |
| 2018-12-31 | 40.00K shares 10-K · filed 2021-02-25 | |
| 2017-12-31 | 25.00K shares 10-K · filed 2020-02-27 | |
| 2016-12-31 | 57.00K shares 10-K · filed 2019-03-18 | |
| 2015-12-31 | 519.00K shares 10-K · filed 2016-02-29 | |
| 2014-12-31 | 541.00K shares 10-K · filed 2015-02-26 | |
| 2013-12-31 | 696.00K shares 10-K · filed 2014-03-12 | |
| 2012-12-31 | 585.00K shares 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |